The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million for Influenza Program
Oct 07, 2024•over 1 year ago
Contract Type
contract
MassachusettsBiotechnologyHealth CareTherapeutics
Description
ModeX Therapeutics Inc. has secured an additional $35 million in funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of a second novel multispecific antibody to SARS-CoV-2 and preclinical work on gene-based expression of multispecific antibodies to SARS-CoV-2. They will also initiate the second phase of BARDA funding through activation of a $16 million option to begin development of influenza multispecifics. The total support awarded to ModeX now amounts to $110 million out of $205 million if all options are executed, and the funding will further explore ModeX’s proprietary MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
Company Information
Company
ModeX Therapeutics
Location
Massachusetts, United States
About
ModeX Therapeutics Inc. is a company focused on developing multispecific antibodies to address viral threats and outbreaks.
Predictive Intelligence
Strategic
ML-powered predictions for ModeX Therapeutics's next move
MassachusettsBiotechnologyHealth CareTherapeutics